Cargando…

Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine

BACKGROUND: Cancer is a somatic evolutionary disease and adenocarcinomas of the stomach and gastroesophageal junction (GC) may serve as a two-dimensional model of cancer expansion, in which tumor subclones are not evenly mixed during tumor progression but rather spatially separated and diversified....

Descripción completa

Detalles Bibliográficos
Autores principales: Röcken, Christoph, Amallraja, Anu, Halske, Christine, Opasic, Luka, Traulsen, Arne, Behrens, Hans-Michael, Krüger, Sandra, Liu, Anne, Haag, Jochen, Egberts, Jan-Hendrik, Rosenstiel, Philip, Meißner, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576943/
https://www.ncbi.nlm.nih.gov/pubmed/34749812
http://dx.doi.org/10.1186/s13073-021-00975-y
_version_ 1784595979533549568
author Röcken, Christoph
Amallraja, Anu
Halske, Christine
Opasic, Luka
Traulsen, Arne
Behrens, Hans-Michael
Krüger, Sandra
Liu, Anne
Haag, Jochen
Egberts, Jan-Hendrik
Rosenstiel, Philip
Meißner, Tobias
author_facet Röcken, Christoph
Amallraja, Anu
Halske, Christine
Opasic, Luka
Traulsen, Arne
Behrens, Hans-Michael
Krüger, Sandra
Liu, Anne
Haag, Jochen
Egberts, Jan-Hendrik
Rosenstiel, Philip
Meißner, Tobias
author_sort Röcken, Christoph
collection PubMed
description BACKGROUND: Cancer is a somatic evolutionary disease and adenocarcinomas of the stomach and gastroesophageal junction (GC) may serve as a two-dimensional model of cancer expansion, in which tumor subclones are not evenly mixed during tumor progression but rather spatially separated and diversified. We hypothesize that precision medicine efforts are compromised when clinical decisions are based on a single-sample analysis, which ignores the mechanisms of cancer evolution and resulting intratumoral heterogeneity. Using multiregional whole-exome sequencing, we investigated the effect of somatic evolution on intratumoral heterogeneity aiming to shed light on the evolutionary biology of GC. METHODS: The study comprised a prospective discovery cohort of 9 and a validation cohort of 463 GCs. Multiregional whole-exome sequencing was performed using samples form 45 primary tumors and 3 lymph node metastases (range 3–10 tumor samples/patient) of the discovery cohort. RESULTS: In total, the discovery cohort harbored 16,537 non-synonymous mutations. Intratumoral heterogeneity of somatic mutations and copy number variants were present in all tumors of the discovery cohort. Of the non-synonymous mutations, 53–91% were not present in each patient’s sample; 399 genes harbored 2–4 different non-synonymous mutations in the same patient; 175 genes showed copy number variations, the majority being heterogeneous, including CD274 (PD-L1). Multi-sample tree-based analyses provided evidence for branched evolution being most complex in a microsatellite instable GC. The analysis of the mode of evolution showed a high degree of heterogeneity in deviation from neutrality within each tumor. We found evidence of parallel evolution and evolutionary trajectories: different mutations of SMAD4 aligned with different subclones and were found only in TP53 mutant GCs. CONCLUSIONS: Neutral and non-neutral somatic evolution shape the mutational landscape in GC along its lateral expansions. It leads to complex spatial intratumoral heterogeneity, where lymph node metastases may stem from different areas of the primary tumor, synchronously. Our findings may have profound effects on future patient management. They illustrate the risk of mis-interpreting tumor genetics based on single-sample analysis and open new avenues for an evolutionary classification of GC, i.e., the discovery of distinct evolutionary trajectories which can be utilized for precision medicine. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13073-021-00975-y.
format Online
Article
Text
id pubmed-8576943
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85769432021-11-10 Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine Röcken, Christoph Amallraja, Anu Halske, Christine Opasic, Luka Traulsen, Arne Behrens, Hans-Michael Krüger, Sandra Liu, Anne Haag, Jochen Egberts, Jan-Hendrik Rosenstiel, Philip Meißner, Tobias Genome Med Research BACKGROUND: Cancer is a somatic evolutionary disease and adenocarcinomas of the stomach and gastroesophageal junction (GC) may serve as a two-dimensional model of cancer expansion, in which tumor subclones are not evenly mixed during tumor progression but rather spatially separated and diversified. We hypothesize that precision medicine efforts are compromised when clinical decisions are based on a single-sample analysis, which ignores the mechanisms of cancer evolution and resulting intratumoral heterogeneity. Using multiregional whole-exome sequencing, we investigated the effect of somatic evolution on intratumoral heterogeneity aiming to shed light on the evolutionary biology of GC. METHODS: The study comprised a prospective discovery cohort of 9 and a validation cohort of 463 GCs. Multiregional whole-exome sequencing was performed using samples form 45 primary tumors and 3 lymph node metastases (range 3–10 tumor samples/patient) of the discovery cohort. RESULTS: In total, the discovery cohort harbored 16,537 non-synonymous mutations. Intratumoral heterogeneity of somatic mutations and copy number variants were present in all tumors of the discovery cohort. Of the non-synonymous mutations, 53–91% were not present in each patient’s sample; 399 genes harbored 2–4 different non-synonymous mutations in the same patient; 175 genes showed copy number variations, the majority being heterogeneous, including CD274 (PD-L1). Multi-sample tree-based analyses provided evidence for branched evolution being most complex in a microsatellite instable GC. The analysis of the mode of evolution showed a high degree of heterogeneity in deviation from neutrality within each tumor. We found evidence of parallel evolution and evolutionary trajectories: different mutations of SMAD4 aligned with different subclones and were found only in TP53 mutant GCs. CONCLUSIONS: Neutral and non-neutral somatic evolution shape the mutational landscape in GC along its lateral expansions. It leads to complex spatial intratumoral heterogeneity, where lymph node metastases may stem from different areas of the primary tumor, synchronously. Our findings may have profound effects on future patient management. They illustrate the risk of mis-interpreting tumor genetics based on single-sample analysis and open new avenues for an evolutionary classification of GC, i.e., the discovery of distinct evolutionary trajectories which can be utilized for precision medicine. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13073-021-00975-y. BioMed Central 2021-11-08 /pmc/articles/PMC8576943/ /pubmed/34749812 http://dx.doi.org/10.1186/s13073-021-00975-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Röcken, Christoph
Amallraja, Anu
Halske, Christine
Opasic, Luka
Traulsen, Arne
Behrens, Hans-Michael
Krüger, Sandra
Liu, Anne
Haag, Jochen
Egberts, Jan-Hendrik
Rosenstiel, Philip
Meißner, Tobias
Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine
title Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine
title_full Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine
title_fullStr Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine
title_full_unstemmed Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine
title_short Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine
title_sort multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576943/
https://www.ncbi.nlm.nih.gov/pubmed/34749812
http://dx.doi.org/10.1186/s13073-021-00975-y
work_keys_str_mv AT rockenchristoph multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine
AT amallrajaanu multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine
AT halskechristine multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine
AT opasicluka multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine
AT traulsenarne multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine
AT behrenshansmichael multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine
AT krugersandra multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine
AT liuanne multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine
AT haagjochen multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine
AT egbertsjanhendrik multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine
AT rosenstielphilip multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine
AT meißnertobias multiscaleheterogeneityingastricadenocarcinomaevolutionisanobstacletoprecisionmedicine